Pancreatic Cancer Research

ResearcherUniversity of UtahNo recent work listed

Douglas G. Adler

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3214-6285; OpenAlex author ID A5021880991. Sources: OpenAlex.

Their work

Papers
9 (first author 1, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
31
Papers, trials and grants by year

2013: 3 papers · 2014: 3 papers · 2015: none · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: none · 2023: 1 paper

Papers 9

  1. Multianalyte Serum Biomarker Panel for Early Detection of Pancreatic Adenocarcinoma. Co-author DOI 10.1200/cci.22.00160↗
  2. Early- and late-onset pancreatic adenocarcinoma: A population-based comparative study. Last author DOI 10.1016/j.pan.2020.12.007↗
  3. Exosomes harbor B cell targets in pancreatic adenocarcinoma and exert decoy function against complement-mediated cytotoxicity. Co-author DOI 10.1038/s41467-018-08109-6↗
  4. First reported case of intentional use of a duodenal stent to treat gastric outlet obstruction prior to pancreaticoduodenectomy in a patient with pancreatic ca… First author DOI 10.1007/s10620-013-2895-3↗
  5. Evaluation of TNM status changes between the first two CT scans in patients with pancreatic cancer. Co-author DOI 10.1038/ajg.2014.302↗
  6. Serum IGFBP2 and MSLN as diagnostic and prognostic biomarkers for pancreatic cancer. Co-author DOI 10.1111/hpb.12199↗
  7. Self-expanding metal stents (SEMS) for preoperative biliary decompression in patients with resectable and borderline-resectable pancreatic cancer: outcomes in … Last author DOI 10.1007/s10620-012-2482-z↗
  8. Serum osteopontin and tissue inhibitor of metalloproteinase 1 as diagnostic and prognostic biomarkers for pancreatic adenocarcinoma. Co-author DOI 10.1097/mpa.0b013e31825e354d↗
  9. Screening for pancreatic cancer: why, how, and who? Co-author DOI 10.1097/sla.0b013e31825ffbfb↗

Closest collaborators

The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Matthew A. Firpo · 5 shared papers, 2013–2023 · strength 0.35
  2. Sean J. Mulvihill · 5 shared papers, 2013–2023 · strength 0.35
  3. Katherine E. Poruk · 3 shared papers, 2013–2023 · strength 0.23
  4. Courtney L. Scaife · 3 shared papers, 2013–2023 · strength 0.23
  5. Josh M. Bleicher · 1 shared paper, 2023 · strength 0.14
  6. Alessandra Rosati · 1 shared paper, 2023 · strength 0.14
  7. Kajsa E. Affolter · 1 shared paper, 2023 · strength 0.14
  8. Vincenzo De Laurenzi · 1 shared paper, 2023 · strength 0.14
  9. Maria Caterina Turco · 1 shared paper, 2023 · strength 0.14
  10. Margot De Marco · 1 shared paper, 2023 · strength 0.14
  11. Liberato Marzullo · 1 shared paper, 2023 · strength 0.14
  12. Ignacio Garrido‐Laguna · 1 shared paper, 2023 · strength 0.14
  13. Daryl Ramai · 1 shared paper, 2021 · strength 0.14
  14. Saurabh Chandan · 1 shared paper, 2021 · strength 0.14
  15. Gandhi Lanke · 1 shared paper, 2021 · strength 0.14
  16. Sarah Ahmad · 1 shared paper, 2014 · strength 0.09
  17. Matthew H. G. Katz · 1 shared paper, 2019 · strength 0.07
  18. Haley L. Peters · 1 shared paper, 2019 · strength 0.07
  19. Michela Capello · 1 shared paper, 2019 · strength 0.07
  20. Jody V. Vykoukal · 1 shared paper, 2019 · strength 0.07
  21. Leonidas E. Bantis · 1 shared paper, 2019 · strength 0.07
  22. Vincent Bernard · 1 shared paper, 2019 · strength 0.07
  23. Randall E. Brand · 1 shared paper, 2019 · strength 0.07
  24. Samir Hanash · 1 shared paper, 2019 · strength 0.07
  25. Anirban Maitra · 1 shared paper, 2019 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.